Ana
Gutiérrez Casbas
Publicacións nas que colabora con Ana Gutiérrez Casbas (20)
2024
-
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry
Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
2021
-
Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study)
Alimentary Pharmacology and Therapeutics, Vol. 54, Núm. 8, pp. 1041-1051
2020
-
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
Clinical and translational gastroenterology, Vol. 11, Núm. 8, pp. e00218
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
-
Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG
Gastroenterologia y Hepatologia, Vol. 43, Núm. 6, pp. 332-347
2019
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
-
Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 13, Núm. 11, pp. 1380-1386
-
Increased risk of thiopurine-related adverse events in elderly patients with IBD
Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788
-
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 3, pp. 278-288
2017
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131
2016
-
Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study
American Journal of Gastroenterology, Vol. 111, Núm. 2, pp. 261-268
-
Erratum: Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC Study (Am J Gastroenterol (2016) 111 (261268) DOI: 10.1038/ajg.2015.403)
American Journal of Gastroenterology
2005
-
Glucogenosis tipo III asociada a carcinoma hepatocelular
Gastroenterologia y Hepatologia, Vol. 28, Núm. 10, pp. 622-625